[Current Situation of Growth and Development and Blood Transfusion Treatment of Patients with Thalassemia in Western Guangxi Region].
Source: PubMed, NCBI / U.S. National Library of Medicine
To investigate the growth and development status and transfusion treatment of thalassemia patients with regular blood transfusion in western Guangxi region, and analyze the related influencing factors. A total of 135 patients with thalassemia who received long-term blood transfusion in the Affiliated Hospital of Youjiang Medical University for Nationalities from May 2022 to May 2023 were selected as the study objects. A self-made questionnaire combined with the medical record management system was used to collect the general information of the patients, basic information of patients' parents, satisfaction with medical services, growth and development status, and blood transfusion treatment. Among the 135 patients with thalassemia, 69 (51.1%) showed normal growth and development, 49 (36.3%) exhibited growth retardation, 50 (37.0%) had weight loss, 10.4% had severe anemia, 54.1% had severe iron overload, and 14.1% failed to achieve regular blood transfusion treatment. The mean hemoglobin (Hb) level before transfusion was (75.75±12.53) g/L (median was 77 g/L). In the irregular blood transfusion group, patients were older, the average annual number of blood transfusions was less, suffered from more severe anemia but milder iron overload, had lower pre-transfusion hemoglobin levels, the compliance of iron removal treatment was poor, and most patients were α-thalassemia (all<0.05). There were significant differences in age, duration of blood transfusion, Hb level before
Abstract
To investigate the growth and development status and transfusion treatment of thalassemia patients with regular blood transfusion in western Guangxi region, and analyze the related influencing factors. A total of 135 patients with thalassemia who received long-term blood transfusion in the Affiliated Hospital of Youjiang Medical University for Nationalities from May 2022 to May 2023 were selected as the study objects. A self-made questionnaire combined with the medical record management system was used to collect the general information of the patients, basic information of patients' parents, satisfaction with medical services, growth and development status, and blood transfusion treatment. Among the 135 patients with thalassemia, 69 (51.1%) showed normal growth and development, 49 (36.3%) exhibited growth retardation, 50 (37.0%) had weight loss, 10.4% had severe anemia, 54.1% had severe iron overload, and 14.1% failed to achieve regular blood transfusion treatment. The mean hemoglobin (Hb) level before transfusion was (75.75±12.53) g/L (median was 77 g/L). In the irregular blood transfusion group, patients were older, the average annual number of blood transfusions was less, suffered from more severe anemia but milder iron overload, had lower pre-transfusion hemoglobin levels, the compliance of iron removal treatment was poor, and most patients were α-thalassemia (all<0.05). There were significant differences in age, duration of blood transfusion, Hb level before blood transfusion, SF level, hepatomegaly, splenomegaly and compliance between normal and abnormal growth and development groups (all<0.05). The results of the survey in the western Guangxi region reflect the living status of patients with thalassemia in the remote areas of southern China to a certain extent. The growth and development abnormalities are common in patients with thalassemia, and associated with advancing age, prolonged transfusion duration, severe iron overload and blood transfusion compliance. Regular monitoring of patients' height, weight, Hb and SF levels, and timely adjustment of blood transfusion and iron removal treatment based on patients' actual growth and development, can help improve the long-term prognosis.